HOUSE_OVERSIGHT_024908.jpg
2.13 MB
Extraction Summary
1
People
3
Organizations
0
Locations
2
Events
1
Relationships
3
Quotes
Document Information
Type:
Financial research report / equity research
File Size:
2.13 MB
Summary
This page is an excerpt from a Cowen equity research report dated February 25, 2019, analyzing GW Pharmaceuticals' clinical trials of CBD (Epidiolex/GWP42003) for schizophrenia and seizures (LGS). The text details positive statistical outcomes and safety profiles compared to placebos. While the document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional document production (likely related to a subpoena of financial institutions), the content itself is purely medical and financial analysis and does not explicitly mention Jeffrey Epstein or his associates on this specific page.
People (1)
| Name | Role | Context |
|---|---|---|
| Michael Cella | Recipient |
Named in the sidebar watermark as the intended recipient of the report (michael.cella@cowen.com).
|
Organizations (3)
| Name | Type | Context |
|---|---|---|
| Cowen |
Investment bank/financial services company publishing the report.
|
|
| GW Pharma |
Pharmaceutical company being analyzed regarding their CBD studies.
|
|
| House Oversight Committee |
Implied by the Bates stamp 'HOUSE_OVERSIGHT_024908'.
|
Relationships (1)
Email address michael.cella@cowen.com found in watermark.
Key Quotes (3)
"CBD consistently demonstrated superiority to placebo, suggesting that CBD may have substantial anti-psychotic effects."Source
HOUSE_OVERSIGHT_024908.jpg
Quote #1
"Even in the context of schizophrenia, CBD produced a clean safety profile, with no serious adverse events and a balanced incidence of adverse events compared to placebo."Source
HOUSE_OVERSIGHT_024908.jpg
Quote #2
"This report is intended for michael.cella@cowen.com. Unauthorized redistribution of this report is prohibited."Source
HOUSE_OVERSIGHT_024908.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document